*By Christian Smith*
After an overdose earlier this week, Demi Lovato's life was reportedly saved by Narcan, a nasal administrator of naloxone that counteracts the effects of opioids. When administered quicklyーthrough either nasal mist or injectionーnaloxone can temporarily halt an overdose, allowing EMTs enough time to respond. The medication is available without a prescription in 49 states, and the generic version costs about $20 per dose.
But all merits aside, is the drug's accessibility enabling addicts to push their limits?
Dr. Roger Crystal, the lead inventor of Narcan and CEO of Opiant Pharmaceuticals, says there's little evidence to support that concern.
"Addiction like any kind of chronic disease is something you can control using better medication, but ultimately you can't cure," Crystal told Cheddar. "To think about an opioid addict behaving rationally and saying, 'well because I have access to Narcan I'll shoot more heroin, inject more heroin' there's no proof for that whatsoever."
Naloxone is considered some of the best ammunition on the front lines of America's growing opioid epidemic. A reported 2 million Americans have an addition to opioidsーand the number isn't going down. U.S. Surgeon General Jerome Adams [issued an advisory](https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html) in April urging anyoneーand their close family and friendsーwho uses painkillers, heroin, fentanyl, or other opioids to carry naloxone in case of an emergency.
Crystal isn't stopping at Narcan: he told Cheddar he's also developing a heroin vaccine, suggesting the inventor has lofty ambitions for the future of overdose prevention.
Although Crystal may be aware of lingering ethical concerns, he doesn't think they dwarf his mission. After all, Lovato has him to thank.
"Putting it in the hands of everyone and anyone is critical," Crystal said.
For more on this story, [click here](https://cheddar.com/videos/how-one-pharmaceutical-company-is-fighting-the-opioid-epidemic).
A trio of scientists is championing a controversial alternative to coronavirus lockdowns in a 500-word document called the Great Barrington Declaration, which is stirring up significant backlash from other public health experts.
Panera is doing its part to go green, upgrading its menu options to include the carbon footprint of each item. CEO Niren Chaudhary joined Cheddar to break down food production's link to climate change.
Former NASA astronaut, Scott Kelly provides some insight into the impacts of being isolated, particularly as people around the world experience it amid the coronavirus pandemic.
US Scientists calculate that Earth hit its warmest September on record last month. The National Oceanic and Atmospheric Administration Wednesday said there's nearly a two-to-one chance that 2020 will end up as the hottest year on record.
Facing public skepticism about rushed COVID-19 vaccines, U.S. health officials are planning an extra layer of safety scrutiny for the first people vaccinated when shots become available.
A late-stage study of Johnson & Johnson’s COVID-19 vaccine candidate has been paused while the company investigates whether a study participant’s “unexplained illness” is related to the shot.
At least 2 percent of American children are being raised by their grandparents, an arrangement that already has unique challenges for such families, but the COVID-19 pandemic is adding even more obstacles to contend with.
From Wall Street to Silicon Valley, these are the top stories that moved markets and had investors, business leaders, and entrepreneurs talking this week on Cheddar.
A 67 million-year-old Tyrannosaurus rex skeleton sold at Christie's Auction House for a record-shattering $31.8 million. Cheddar's Chloe Aiello takes a look into the sale of the massive complete fossil and Christie's virtual auction process.
Democratic lawmakers are speaking out against a proposed Labor Department rule that they argue would make it harder for retirement funds to consider important environmental factors when making investment decisions.
